根據2023年統計，大腸癌為全球第三大常見癌症，也是全球癌症相關死亡的第二大原因，台灣人的發病率更是亞洲第一。這些數據反映了大腸癌新病例的發生情況，突顯了對其治療的重視。大腸癌是一種高度侵襲性且容易轉移的癌症，具有較高的發病率和致命性。在全球範圍內，大腸癌的發病率持續上升，對患者的生活質量和健康帶來了嚴重挑戰。 本研究開發的ICFExo結合傳統化學治療與新興光治療技術，包括光熱治療（Photothermal therapy, PTT）與光動力治療（Photodynamic therapy, PDT），並運用奈米載體技術，旨在大量減少抗癌藥物的使用量，從而降低藥物相關的副作用。由此構思開發出一種載有靛青綠光敏劑及喜樹鹼化療藥物的外泌體，並具備追蹤至癌細胞的能力。該外泌體可原位注射至腫瘤部位，並結合全氟碳化物，協同光治療與化學治療，多種不同的治療方式，達到精準治療並降低化學治療所導致的副作用。 本研究證實ICFExo具有龐大的治療潛力，無論在體外功能測試還是體內治療效果上，都顯示優良的治療效果。預期未來可在臨床中取得良好成果。;According to statistics in 2023, Colorectal cancer ranks as the third most prevalent cancer globally and standing as the second leading cause of cancer-related mortality worldwide. In Taiwan, the incidence rate is the highest in Asia. These data reflect the incidence of new cases of colorectal cancer, highlighting the importance of focusing on its treatment. Colorectal cancer is a highly invasive and metastatic cancer with a relatively high incidence and mortality rate. Globally, the incidence of colorectal cancer continues to rise, posing a significant challenge to patients′ quality of life and overall health. The ICFExo developed in this study combines traditional chemotherapy with emerging phototherapy techniques, including photothermal therapy (PTT) and photodynamic therapy (PDT), and utilizes nanocarrier technology. The aim is to significantly reduce the use of anticancer drugs, thereby minimizing drug-related side effects. Based on this concept, we developed an exosome loaded with indocyanine green photosensitizer and camptothecin chemotherapy drug, which also possesses the ability to track cancer cells. This exosome can be locally injected into tumor sites and combined with perfluorocarbons, synergizing phototherapy and chemotherapy through multiple therapeutic modalities. This approach achieves precise treatment while reducing the side effects associated with chemotherapy. This study confirms that ICFExo holds great therapeutic potential. Both in vitro functional assays and in vivo therapeutic outcomes demonstrate its ability to accurately target colorectal cancer cells. It is expected to achieve promising clinical outcomes in the future.
